Title
Category
Credits
Event date
Cost
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Puneet Singh Jolly, MD, PhD discusses keratinocyte neoplasms are by far the most common malignancy in the world. While surgical treatments remain the most common and most effective therapy, there are numerous emerging non-surgical techniques. We discuss these and the rationale for using such treatments, particularly in specific challenging clinical scenarios.
  • 0.75 NCPD/CNE
  • 1.00 Participation
$0.00
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will provide a general overview of Prostate Cancer. The audience will learn about basic pathophysiology and epidemiology as it relates to both local and advanced disease. This course will then provide insight into the pros & cons of prostate cancer screening as well as the accepted diagnostic procedures & scoring.
  • 0.75 NCPD/CNE
  • 1.00 Participation
$0.00
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will go into more detail for treatment options and considerations for treating localized prostate cancer and the management of side effects.
  • 0.75 NCPD/CNE
  • 1.00 Participation
$0.00
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will discuss the different treatment options for advanced prostate cancer as well as considerations for management side effects and maximizing a survivor’s quality of life.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Marc Bjurlin, DO, MSc, FACOS, gives a contemporary overview of prostate cancer screening with a focus on prostate cancer in men in North Carolina.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 CTR
  • 1.00 Participation
$0.00
Erin Kent, PhD, MSc, and Loretta Muss, RN, BA, discuss how to recruit the caregiver into the patient’s plan of care and understanding the role and the stresses of being an oncology caregiver.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.50 ASRT
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Join Maggie M. Hodges, MD, MPH, for a surgeon's perspective on the role of cancer risk reduction through bariatric surgery, while also exploring the optimal timing of bariatric surgery in patients with a personal history of cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Siddharth Sheth, DO, MPH, will provide a brief overview of clinical factors relevant to head and neck cancers and basic management. Themain focus will be the current use of technologies that aid with the diagnosis, treatment selection, and monitoring of patientswith head and neck cancers. This includes next generation sequencing assays for DNA sequencing, RNA sequencing, andcirculating tumor DNA. The goal of the presentation is for providers to be comfortable with ordering and basic interpretation ofthese tests.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 Participation
$0.00
Yara Abdou, MD, will delve into various aspects of early breast cancer, covering an overview of the epidemiological landscape of early-stage breast cancer, current screening guidelines, various subtypes of breast cancer and an overview of latest treatment strategies early breast cancer. The webinar will conclude with a focus on post-treatment surveillance and follow-up care for early breast cancer survivors.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Michael Galgano, MD, FAANS, will focus on differentiating the various types of spinal tumors, ranging from metastases, to primary vertebral column tumors, and intradural spinal cord tumors. He will discus the contributions of co-morbidities and frailty on the management of patients with spinal tumors. He will also aim to give the audience a brief exposure to the surgical management of spinal oncology, and what is entailed to execute robust local control.

Pages